Dr. Reddy's Laboratories is a global pharmaceutical company offering generic medicines, biosimilars, and differentiated formulations. It operates in major markets like the USA, India, Russia, and Europe.

In Q2FY26, the company saw a 10% year-over-year increase in revenues due to the integration of consumer healthcare businesses and double-digit growth in various markets, supported by favorable forex conditions.

The company continues to expand its biosimilars portfolio, with a positive opinion for denosumab biosimilar and approval pursuit for Semaglutide, highlighting significant advancements in their biotechnology endeavors.

Recent acquisitions and partnerships bolster Dr. Reddy's presence in consumer healthcare and diversify its product offerings, exemplified by the acquisition of Stugeron® brands and collaboration for Abatacept production.

ESG initiatives are a major focus for Dr. Reddy's, evidenced by their 'A' MSCI ESG Rating and their India facilities being recognized for excellent waste management and energy efficiency certifications.